Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Award of the Dr A.T. Shousha Foundation Prize and Fellowship To Dr. Walid Ammar



Regional Committee for the Eastern Mediterranean                                                                    EM/RC63/INF.DOC.7 Rev.1
Sixty-third session                                                                                                                                           September 2016 
Provisional agenda item 9(a)


Award of the Dr A.T. Shousha Foundation Prize and Fellowship
 
  1. Following the recommendations of the Dr A.T. Shousha Foundation Committee at the Sixty-second Session of the World Health Organization (WHO) Regional Committee for the Eastern Mediterranean, the Executive Board awarded the Dr A.T. Shousha Foundation Prize for 2016, by decision EB138(5), to Dr Walid Ammar (Lebanon) for his significant contribution to public health in the geographical area in which Dr Shousha served WHO.
 
  1. Dr Walid Ammar is being honoured for his significant contribution to public health in Lebanon, in particular in the areas of primary health care and health policy, and for his efforts in translating research and evidence into policy, programmes and practice and his efforts to voice the interests of the Region in all WHO forums. Dr Ammar graduated from the medical college of the Université Libre de Bruxelles, Belgium, in 1982, and received a master’s degree in public health and a diplôme d’études approfondies from the Lebanese University in 1996. In 2001, he was awarded a PhD in epidemiology from the Université Victor Segalen in Bordeaux, France (Université Bordeaux II).
 
  1. Since 1993, Dr Ammar has been Director-General of the Ministry of Public Health of Lebanon, bringing together a range of stakeholders to chart a vision for the welfare, rights and health care in an open network model of governance. Among other achievements, Dr Ammar set up Lebanon’s primary health care network in 1994 and initiated the first national hospital accreditation system in the Eastern Mediterranean Region, and was instrumental in strengthening and developing the Lebanese health care system. In a time of political instability and under his leadership, reforms led to significant improvement in health indicators while decreasing the GDP share of health expenditures, mostly as a result of meaningful reduction in household out-of-pocket spending.
 
  1. Dr Ammar is a model for public health professionals, having served not only in government and in the academic community but also in numerous national, regional and international organizations, boards and councils. Dr Ammar has produced numerous publications in the areas of health systems, health reform and good governance. His work as a researcher has led to the development of major studies which have been pivotal in reforming the health care system of Lebanon. 
Attribution du Prix et de la Bourse d’études de la Fondation Dr A.T. Shousha a Dr. Walid Ammar
 
Awarding Ceremony, Cairo, October 3, 2016-Laureat address-Walid Ammar MD, Ph.D



    ...
    8
    ...
ATC Name B/G Ingredients Dosage Form Price
L03AB11 PEGASYS BioTech Peginterferon alfa-2a - 180mcg/0.5ml 180mcg/0.5ml Injectable solution 18,197,019 L.L
L03AB11 PEGASYS BioTech Peginterferon alfa-2a - 180mcg/0.5ml 180mcg/0.5ml Injectable solution 60,563,068 L.L
L03AB11 PEGASYS BioTech Peginterferon alfa-2a - 180mcg/0.5ml 180mcg/0.5ml Injectable solution L.L
N06BA09 PMS-ATOMOXETINE G Atomoxetine (HCl) - 18mg 18mg Capsule 3,744,073 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Tablet, controlled release 4,945,340 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Suppository 4,153,817 L.L
A07EC02 PENTASA B Mesalazine - 1g 1g Enema 2,791,161 L.L
J01CR02 POSMOX G Amoxicillin (trihydrate) - 875mg, Clavulanic Acid (potassium) - 125mg 1g Powder 616,824 L.L
N02BE01 PARACETAMOL ARROW G Paracetamol - 1g 1g Tablet 80,631 L.L
N02BE01 PARASWISS G Paracetamol - 1g/100ml 1g/100ml Injectable solution 130,353 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule 25,241,922 L.L
L04AD02 PROGRAF 1MG B Tacrolimus - 1mg 1mg Capsule L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg 1mg Tablet 823,775 L.L
N05AX08 PMS-RISPERIDONE G Risperidone - 1mg/ml 1mg/ml Solution 604,729 L.L
R05CB13 PULMOZYME BioTech Dornase alfa (desoxyribonuclease) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution L.L
R05CB13 PULMOZYME BioTech Dornase alfa (desoxyribonuclease) - 2.5mg/2.5ml 2.5mg/2.5ml Inhalation solution 54,658,804 L.L
B05AA01 PLASBUMIN-20 ALBUMIN (HUMAN) BioHuman Albumin human - 20% 20% Injectable solution 3,641,813 L.L
B01AB05 PARINOX 20 BioTech Enoxaparin sodium - 2000IU (20mg)/0.2ml 2000IU (20mg)/0.2ml Injectable solution 188,138 L.L
N05CM18 PRECEDEX (DEXMEDETOMIDINE) B Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable solution 19,441,512 L.L
N05CM18 PROXIDA G Dexmedetomidine HCl - 200mcg/2ml 200mcg/2ml Injectable concentrate for solution 1,771,184 L.L
G03DA04 PROGEST 200 G Progesterone micronised - 200mg 200mg Capsule, soft gelatin 411,216 L.L
G03DA04 PROGEST 200 G Progesterone micronised - 200mg 200mg Capsule, soft gelatin 411,216 L.L
V03AB35 PLIBADEX G Sugammadex - 200mg/2ml 200mg/2ml Injectable solution 47,914,365 L.L
C10AA03 PRAVASTATINE ARROW G Pravastatin - 20mg 20mg Tablet, breakable 526,786 L.L
L04AE04 PONVORY B Ponesimod - 20mg 20mg Tablet, film coated 74,118,566 L.L
A02BC02 PANTO TAD G Pantoprazole (sodium) - 20mg 20mg Tablet, gastroresistant 294,302 L.L
A02BC02 PANTOMAX G Pantoprazole (sodium sesquihydrate) - 20mg 20mg Tablet, enteric coated 440,780 L.L
A02BC02 PANTOMAX G Pantoprazole (sodium sesquihydrate) - 20mg 20mg Tablet, enteric coated 837,214 L.L
A02BC04 PARIET B Rabeprazole (sodium) - 20mg 20mg Tablet, gastroresistant 779,429 L.L
    ...
    8
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026